 NHS patients could lose out on access to groundbreaking new drug treatments after two major pharmaceutical companies ditched a scheme that limits the amount of money spent on new medicines for the health service. Under the Voluntary Scheme for Branded Medicines Pricing and Access, VPAS, an agreement exists between the Government, NHS and medicine manufacturers ... NHS patients risk of losing access to breakthrough drugs... 